Global Gout Therapeutics Market, By Type (NSAIDs, Corticosteroids, Diuretics), Treatment (Xanthine Oxidase Inhibitor, Uricosuria Medication), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Gout Therapeutics Market Analysis and Size
As per the data by The World Bank, in 2019, non-communicable diseases caused 74% of deaths worldwide. According to numerous studies, the occurrence and incidence of gout have increased in the last few decades. Gout treatment demands both pharmacological and non-pharmacological measures. Men can be three times more likely to have gout than women as they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.
Data Bridge Market Research analyses a growth rate in the gout therapeutics market in the forecast period 2023-2030. The expected CAGR of gout therapeutics market is tend to be around 8.9% in the mentioned forecast period. The market was valued at USD 2.40 billion in 2022, and it would grow upto USD 4.75 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Gout Therapeutics Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 – 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (NSAIDs, Corticosteroids, Diuretics), Treatment (Xanthine Oxidase Inhibitor, Uricosuria Medication), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Antares Pharma (U.S.), Astellas Pharma Inc. (Japan), Can-Fite BioPharma, JW Pharmaceutical Corporation (South Korea), Addex Therapeutics (Switzerland), Takeda Pharmaceutical Company Limited (Japan), TEIJIN LIMITED (Japan)., Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.)
Gout is a type of inflammatory arthritis that is developed above the age of 40 years amongst males who are having high level of uric acid in the blood. It is more prevalent in males than females. The acid can form needle type crystals in joints and can cause serious pain, swelling and tenderness. Gout is a common form of inflammatory arthritis which is quite painful. It generally affects one joint at a time. There are times when symptoms get worse, known as flares, and then there are times when there are no symptoms termed as remission.
Global Gout Therapeutics Market Dynamics
- High Occurrence of Arthritis
It has been observed that more than 350 million people have arthritis worldwide. In the U.S., 1 in 4 adults have been recorded with arthritis in 2020. It is anticipated to be 78 million by the year 2040. In addition, in the U.S., about 52.2 million people were affected with rheumatoid arthritis in 2013. This boosts the market growth. Thus, this disease prevalence leads to gout development and in return demands higher therapeutics globally.
- High Incidence of Chronic Diseases
As per a 2014 study published in the Journal of Rheumatology, about 75% of patients with gout have high blood pressure. Thus, patients suffering from chronic illness are at increased risk of developing gout. The increasing prevalence of gouty arthritis is projected to drive market growth.
- Rising Collaborations Between Market Players and Organizations
There have been growing collaborations between different key players that result in the market growth. For instance, in June 2021, Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH. It is a previously unknown discovery-stage investigational RNA interference (RNAi) therapeutic that is being developed by Arrowhead as a potential treatment for uncontrolled gout.
- Increasing Demand of NSAIDs
NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), are the treatment of choice for the majority of acute gout patients. There is no data that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.
- Lack Of Resources In Under-Developed Nations
The under-developed countries or regions do not have adequate resources for the development of gout therapeutics. Therefore, lack of resources in many of these countries pose a major hindrance for the expansion of market globally.
- High Cost of Treatment
The increasing cost of pharmaceuticals is very expensive and it gets difficult for an average person to afford the treatment. There are many therapy types and drugs that are quite expensive and therefore pose a major limitation to the market.
This gout therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gout therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In 2022, Synlogic, Inc., which is a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases, announced the development of a new drug candidate used for the treatment of gout in collaboration with Ginkgo Bioworks which is a leading horizontal platform for cell programming
- In 2022, Horizon Therapeutics' supplemental Biologics License Application (sBLA) for the Krystexxa (pegloticase) injection, which is given in conjunction with methotrexate, to treat uncontrolled gout patients, achieve a complete response to treatment received U.S. FDA approval
Global Gout Therapeutics Market Scope
The gout therapeutics market is segmented on the basis of type, treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Xanthine Oxidase Inhibitor
- Uricosuria Medication
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
Gout Therapeutics Market Regional Analysis/Insights
The gout therapeutics market is analyzed and market size insights and trends are provided by type, treatment, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the gout therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the presence of key product manufacturing, high research and development and growing healthcare expenditure.
Asia-Pacific is expected to account for the largest market share due to the increased incidence of evolving lifestyles related with hypertension, kidney and liver disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Gout Therapeutics Market Share Analysis
The gout therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gout therapeutics market.
Key players operating in the gout therapeutics market include:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc (U.K.)
- Antares Pharma (U.S.)
- Astellas Pharma Inc. (Japan)
- JW Pharmaceutical Corporation (South Korea)
- Addex Therapeutics (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- TEIJIN LIMITED (Japan)
- Lilly (U.S.)